Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Ascot Brewing are passionate brewing award-winning real ales and hop-forward craft beers. They are on a mission to deliver value for its shareholders and customers while providing opportunities for its employees. They have opened a 2,500sq ft,20 tap - taproom and launched its hop-forward craft beer brand. Till now there are 785 investors backing Ascot Brewing Company and they have recently moved to new 8,500 sq. Ft building & installed new brewing kit. The company have successfully launched our hop-forward craft beer brand (Disruption is Brewing®). Ascot Brewing is seeking investment to expand the sales team, build out one of the best taprooms in the UK, growing export trade, add a small canning line, and address export inquiries.
days to go:
Expired
investment:
£150,000
Doodle Drinks (DD) aims to make all-natural soft drinks that kids can enjoy. The company cites research data arguing that children aged 18 months to 18 years are drinking 26% fewer sugary drinks and consumption for 10-year olds has fallen 35%. It wants to capture this sentiment and deliver a soft drink that's a healthy choice for both parents and their kids. DD has secured distribution with the noted distributor, Bravura Foods. It has also signed a partnership with the largest independent bottler of beverages in Europe and North America, Refresco, who have over 60 manufacturing sites globally to fulfil its objective. DD will use the investment to grow its business, execute its marketing strategy and increase its product range.
days to go:
Expired
investment:
£877,830
TheVeganKind is a plant-based supermarket subscription box service that sells different vegan and plant-based products. The company has generated a revenue of £2.5m during Nov 2018-Nov 2019. TheVeganKind had shipped more than 130,000 orders alone in 2019. There are more than 4,500 different vegan and plant-based products in stock. It has been recently voted the UK's Top Online Retailer for Vegan Shopping. TheVeganKind has more than 500,000 social followers across Facebook, Twitter, and Instagram. With the proceeds, the company will allocate 60% of the funds towards marketing and branding; 20% will go towards warehouse expansion, and in increasing its inventory; 20% will go towards operating expenditure and team expansion.
days to go:
Expired
investment:
£669,188
Nelson's Distillery & School (NDAS) makes and sells craft gin from its 290-litre state-of-the-art establishment. It also educates interested folks from its 28 seat Gin school in the art of making quality craft gin. Former Chef and founder, Neil Harrison, set out to create the best craft Gin and to educate others in the process. The company has produced and sold over 100,000 bottles since its founding in 2019. It aspires to become a contender in the global gin market valued at $15 billion. NDAS asserts that it is one of a few craft gin companies to win the coveted 3-star Great British Taste award, plus 6 other awards over 2 years. The company has also signed four contracts with the Hilton & Clayton hotels, three in the UK and one in Asia. NDAS will use the investment to expand its business and establish Nelson’s Gin school in all major cities.
days to go:
Expired
investment:
£317,868
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Propetly is an online platform that acts as a connecting hub between investment providers and global investors in the field of real estate. It enables potential property investors to find, evaluate and calculate their investment project within minutes. With the help of AI-enabled architecture, Propetly can verify transactions on its portal, suggest finance options and ensure complete diligence of the transaction as per industry benchmarks. Given the relative lack of professional and up-to-date property investors in the UK, Propetly aims to become the one-stop-shop for all real estate deals. Its offering has led to Propetly being counted amongst leading PropTech brands in the UK. With the funds received, Propetly will invest in paid advertising and PR, upgrade its AI systems to enable more options are available to customers across wide demographics and human resources.
days to go:
Expired
investment:
£235,079
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. As per reports, mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS believes that its products can keep occupants inside a vehicle completely safe from the aforementioned explosive devices. The armoured vehicle protection market has a value of about $20 billion wherein ABBS aims to be a major contender. The company has received £2 million-plus revenues till date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. It will use the investment to bring its products to more markets globally.
days to go:
Expired
investment:
£445,814
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
